Researchers from IBEC, in collaboration with IDIBAPS in Barcelona, have developed nontoxic small spheres able to respond to variations in glucose levels, and producing insulin in vitro. These biomimetic spheroids containing pancreatic β-cells were prepared based on 3D bioprinting. This approach might help in the future improving clinical outcomes of β-cell transplantation strategies for diabetes treatment, as well as for in vitro drug screening platforms.
